1193 related articles for article (PubMed ID: 27603913)
21. Cancer/testis (CT) antigens: potential targets for immunotherapy.
Caballero OL; Chen YT
Cancer Sci; 2009 Nov; 100(11):2014-21. PubMed ID: 19719775
[TBL] [Abstract][Full Text] [Related]
22. Cancer-testis antigens in canine histiocytic sarcoma and other malignancies.
Nemec PS; Kapatos A; Holmes JC; Stowe DM; Hess PR
Vet Comp Oncol; 2019 Sep; 17(3):317-328. PubMed ID: 30854786
[TBL] [Abstract][Full Text] [Related]
23. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy.
Scanlan MJ; Gure AO; Jungbluth AA; Old LJ; Chen YT
Immunol Rev; 2002 Oct; 188():22-32. PubMed ID: 12445278
[TBL] [Abstract][Full Text] [Related]
24. Cancer-testis antigens: An update on their roles in cancer immunotherapy.
Taherian-Esfahani Z; Dashti S
Hum Antibodies; 2019; 27(3):171-183. PubMed ID: 30909205
[TBL] [Abstract][Full Text] [Related]
25. Expression and Prognostic Relevance of GAGE1 and XAGE1 Cancer/Testis Antigens in Head and Neck Squamous Cell Carcinoma.
Karia BTR; Zamuner FT; Carlin V; de Oliveira CZ; Carvalho AL; Vettore AL
Curr Mol Med; 2017; 17(10):707-717. PubMed ID: 29577858
[TBL] [Abstract][Full Text] [Related]
26. Cause and consequence of cancer/testis antigen activation in cancer.
Whitehurst AW
Annu Rev Pharmacol Toxicol; 2014; 54():251-72. PubMed ID: 24160706
[TBL] [Abstract][Full Text] [Related]
27. Cancer testis antigens as immunogenic and oncogenic targets in breast cancer.
Mahmoud AM
Immunotherapy; 2018 Jul; 10(9):769-778. PubMed ID: 29926750
[TBL] [Abstract][Full Text] [Related]
28. Melanoma: a prototype of cancer-testis antigen-expressing malignancies.
Faramarzi S; Ghafouri-Fard S
Immunotherapy; 2017 Oct; 9(13):1103-1113. PubMed ID: 29032737
[TBL] [Abstract][Full Text] [Related]
29. Expression of cancer-testis antigens in stem cells: is it a potential drawback or an advantage in cancer immunotherapy.
Ghafouri-Fard S
Asian Pac J Cancer Prev; 2015; 16(7):3079-81. PubMed ID: 25854409
[TBL] [Abstract][Full Text] [Related]
30. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
[TBL] [Abstract][Full Text] [Related]
31. Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia.
Atanackovic D; Luetkens T; Kloth B; Fuchs G; Cao Y; Hildebrandt Y; Meyer S; Bartels K; Reinhard H; Lajmi N; Hegewisch-Becker S; Schilling G; Platzbecker U; Kobbe G; Schroeder T; Bokemeyer C; Kröger N
Am J Hematol; 2011 Nov; 86(11):918-22. PubMed ID: 21898529
[TBL] [Abstract][Full Text] [Related]
32. Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses.
Nishimura Y; Tomita Y; Yuno A; Yoshitake Y; Shinohara M
Cancer Sci; 2015 May; 106(5):505-11. PubMed ID: 25726868
[TBL] [Abstract][Full Text] [Related]
33. Expression analysis of cancer-testis genes in prostate cancer reveals candidates for immunotherapy.
Faramarzi S; Ghafouri-Fard S
Immunotherapy; 2017 Sep; 9(12):1019-1034. PubMed ID: 28971747
[TBL] [Abstract][Full Text] [Related]
34. Expression of cancer-testis antigens in the immune microenvironment of non-small cell lung cancer.
Hikmet F; Rassy M; Backman M; Méar L; Mattsson JSM; Djureinovic D; Botling J; Brunnström H; Micke P; Lindskog C
Mol Oncol; 2023 Dec; 17(12):2603-2617. PubMed ID: 37341056
[TBL] [Abstract][Full Text] [Related]
35. Cancer testis antigen burden (CTAB): a novel biomarker of tumor-associated antigens in lung cancer.
Seager RJ; Senosain MF; Van Roey E; Gao S; DePietro P; Nesline MK; Dash DP; Zhang S; Ko H; Hastings SB; Strickland KC; Previs RA; Jensen TJ; Eisenberg M; Caveney BJ; Severson EA; Ramkissoon S; Conroy JM; Pabla S
J Transl Med; 2024 Feb; 22(1):141. PubMed ID: 38326843
[TBL] [Abstract][Full Text] [Related]
36. Roles of cancer/testis antigens (CTAs) in breast cancer.
Li Y; Li J; Wang Y; Zhang Y; Chu J; Sun C; Fu Z; Huang Y; Zhang H; Yuan H; Yin Y
Cancer Lett; 2017 Jul; 399():64-73. PubMed ID: 28274891
[TBL] [Abstract][Full Text] [Related]
37. Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer.
Smith HA; Cronk RJ; Lang JM; McNeel DG
Cancer Res; 2011 Nov; 71(21):6785-95. PubMed ID: 21880588
[TBL] [Abstract][Full Text] [Related]
38. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer.
Groeper C; Gambazzi F; Zajac P; Bubendorf L; Adamina M; Rosenthal R; Zerkowski HR; Heberer M; Spagnoli GC
Int J Cancer; 2007 Jan; 120(2):337-43. PubMed ID: 17066423
[TBL] [Abstract][Full Text] [Related]
39. Cancer/testis antigens and urological malignancies.
Kulkarni P; Shiraishi T; Rajagopalan K; Kim R; Mooney SM; Getzenberg RH
Nat Rev Urol; 2012 Jun; 9(7):386-96. PubMed ID: 22710665
[TBL] [Abstract][Full Text] [Related]
40. Identification of tumor-restricted antigens NY-BR-1, SCP-1, and a new cancer/testis-like antigen NW-BR-3 by serological screening of a testicular library with breast cancer serum.
Jäger D; Unkelbach M; Frei C; Bert F; Scanlan MJ; Jäger E; Old LJ; Chen YT; Knuth A
Cancer Immun; 2002 Jun; 2():5. PubMed ID: 12747750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
